U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07326488) titled 'A Study of MHB009C in Patients With Advanced Solid Tumors' on Dec. 22, 2025.
Brief Summary: This is a first-in-human, open-label, multicenter Phase I/II study of MHB009C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB009C monotherapy.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Malignant Solid Tumor
Intervention:
DRUG: MHB009C for Injection
IV administration of MHB009C Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirm...